摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-oxo-3-tert-butoxycarbonylamino-5-methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepine

中文名称
——
中文别名
——
英文名称
2-oxo-3-tert-butoxycarbonylamino-5-methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepine
英文别名
tert-butyl N-(5-methyl-2-oxo-3,4-dihydro-1H-1,5-benzodiazepin-3-yl)carbamate
2-oxo-3-tert-butoxycarbonylamino-5-methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepine化学式
CAS
——
化学式
C15H21N3O3
mdl
——
分子量
291.35
InChiKey
MPNLQKVSCAXVPD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    21
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.47
  • 拓扑面积:
    70.7
  • 氢给体数:
    2
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists
    申请人:Tung S. Jay
    公开号:US20050020659A1
    公开(公告)日:2005-01-27
    Disclosed are compounds that are bradykinin B 1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B 1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.
    本发明公开了一种布雷肯肽B1受体拮抗剂化合物,可用于治疗哺乳动物中由布雷肯肽B1受体介导的疾病或缓解与疾病状况相关的不良症状。其中某些化合物表现出增强的效力,并且预计也会表现出增强的作用持续时间。
  • 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases
    申请人:Tung S. Jay
    公开号:US20060281733A1
    公开(公告)日:2006-12-14
    Disclosed are compounds of formula I and II that are bradykinin B 1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B 1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.
    本发明公开了式I和式II的化合物,它们是缓激肽B1受体拮抗剂,可用于治疗哺乳动物中由缓激肽B1受体介导的疾病,或缓解与疾病条件相关的不良症状。其中某些化合物表现出增强的效力,预计也会表现出增强的持续时间。
  • 1,5-BENZODIAZEPINE DERIVATIVES
    申请人:ZERIA PHARMACEUTICAL CO., LTD.
    公开号:EP0945445A1
    公开(公告)日:1999-09-29
    1,5-Benzodiazepine derivatives represented by formula (I), salts thereof, and medicines containing the same as the active ingredient: [wherein R1 represents a hydrogen atom, a lower alkyl group, a lower alkoxyl group, or a halogen atom; each of R2 and R3, which may be the same or different, represents a hydrogen atom, an alkenyl group, an alkyl group, a phenyl group, an acyl group, etc; and each of R4 and R5, which may be the same or different, represents a hydrogen atom, an alkyl group, a carboxyl group, etc.]. The compounds exhibit excellent gastrin and/or CCK-B receptor antagonism and are useful as remedies for gastric ulcer and gastrointestinal movement disorder.
    由式(I)代表的 1,5-苯并二氮杂卓衍生物、其盐类以及以其为有效成分的药物: [其中 R1 代表氢原子、低级烷基、低级烷氧基或卤素原子;R2 和 R3(可以相同或不同)分别代表氢原子、烯基、烷基、苯基、酰基等;R4 和 R5(可以相同或不同)分别代表氢原子、烷基、羧基等]。这些化合物具有优异的胃泌素和/或 CCK-B 受体拮抗作用,可用于治疗胃溃疡和胃肠运动紊乱。
  • 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B sb 1 /sb RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES
    申请人:ELAN PHARMACEUTICALS, INC.
    公开号:EP1633348B1
    公开(公告)日:2008-10-08
  • US6239131B1
    申请人:——
    公开号:US6239131B1
    公开(公告)日:2001-05-29
查看更多